Aikaterini Pliatsika
Aikaterini Pliatsika has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Spyros Petrakis
Institute of Applied Biosciences, Centre for Research and Technology Hellas (CERTH), 6th km Charilaou–Thermi Road, Thermi, 57001 Thessaloniki, Greece
2 shared publications - Andreas G. Tzakos
Department of Chemistry, Section of Organic Chemistry and Biochemistry, University of Ioannina, 45110 Ioannina, Greece
1 shared publication Antonis D. Tsiailanis
1 shared publicationApostolos Axenopoulos
Information Technologies Institute
1 shared publication- Christos Chatzigiannis
ICGM, Univ Montpellier, CNRS, ENSCM, Montpellier, France
1 shared publication - Demeter Tzeli
Laboratory of Physical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 157 84 Athens, Greece
1 shared publication
Latest Publications
- Open Access
- 14 April 2026
- Published by Elsevier in SSRN Electronic Journal
Engineering an Intramolecular Lock in NIR AIE Probes for Fluorogenic Sensing of ATXN1 Inclusions
Spinocerebellar ataxia type 1 (SCA1) is a fatal polyglutamine (polyQ) neurodegenerative disorder caused by CAG-repeat expansion in ATXN1, which promotes β-sheet-rich misfolding and formation of intranuclear amyloid inclusions. Given that clinical symptoms appear only after irreversible neurodegeneration, early detection of polyQ inclusions remains a critical unmet need. Here we report two Near Infrared (NIR) Aggregation Induced Emission (AIE) probes, AGT-13 and AGT-12, developed through acceptor-scaffold tuning to control aggregation and fluorogenic response. Starting from a dicyanomethylene-4H-chromene acceptor (AGT-13), we redesigned the acceptor to a dicyanomethylidene-indandione core (AGT-12) to introduce a carbonyl-enabled intramolecular conformational lock (C-H···O=C) that pre-organizes the π-system and is expected to favor aggregation-driven rigidification. Single-crystal X-ray crystallography verified this intramolecular lock in AGT-12, together with extended π-delocalization and π-π stacking in the solid state. Both probes emit in the NIR and display red-shifted AIE behavior; AGT-12 shows a pronounced turn-on with up to ~nine-fold fluorescence enhancement and NIR emission around 766 nm, while AGT-13 exhibits a strong AIE response with emission near 750 nm. DFT calculations are consistent with enhanced aggregation propensity. In an inducible SH-SY5Y model expressing EYFP-ATXN1(Q82), both probes selectively detect polyQ amyloid-like inclusions with dose-dependent signal increases reaching ~10-fold at 10 μM. Finally, intravenous administration in mice demonstrates brain accumulation of both probes, consistent with blood-brain barrier (BBB) permeability. Collectively, acceptor-scaffold redesign to introduce an internal conformational lock provides a design principle for NIR AIE probes and delivers probe candidates for fluorescence-based detection of polyQ-expanded ATXN1 amyloid inclusions relevant to early SCA1 diagnosis.
- 14 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEngineering an Intramolecular Lock in NIR AIE Probes for Fluorogenic Sensing of ATXN1 Inclusions
Spinocerebellar ataxia type 1 (SCA1) is a fatal polyglutamine (polyQ) neurodegenerative disorder caused by CAG-repeat expansion in ATXN1, which promotes β-sheet-rich misfolding and formation of intranuclear amyloid inclusions. Given that clinical symptoms appear only after irreversible neurodegeneration, early detection of polyQ inclusions remains a critical unmet need. Here we report two Near Infrared (NIR) Aggregation Induced Emission (AIE) probes, AGT-13 and AGT-12, developed through acceptor-scaffold tuning to control aggregation and fluorogenic response. Starting from a dicyanomethylene-4H-chromene acceptor (AGT-13), we redesigned the acceptor to a dicyanomethylidene-indandione core (AGT-12) to introduce a carbonyl-enabled intramolecular conformational lock (C-H···O=C) that pre-organizes the π-system and is expected to favor aggregation-driven rigidification. Single-crystal X-ray crystallography verified this intramolecular lock in AGT-12, together with extended π-delocalization and π-π stacking in the solid state. Both probes emit in the NIR and display red-shifted AIE behavior; AGT-12 shows a pronounced turn-on with up to ~nine-fold fluorescence enhancement and NIR emission around 766 nm, while AGT-13 exhibits a strong AIE response with emission near 750 nm. DFT calculations are consistent with enhanced aggregation propensity. In an inducible SH-SY5Y model expressing EYFP-ATXN1(Q82), both probes selectively detect polyQ amyloid-like inclusions with dose-dependent signal increases reaching ~10-fold at 10 μM. Finally, intravenous administration in mice demonstrates brain accumulation of both probes, consistent with blood-brain barrier (BBB) permeability. Collectively, acceptor-scaffold redesign to introduce an internal conformational lock provides a design principle for NIR AIE probes and delivers probe candidates for fluorescence-based detection of polyQ-expanded ATXN1 amyloid inclusions relevant to early SCA1 diagnosis.
- Open Access
- 17 June 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (25) , 27194-27205
Chemical Targeting of the ATXN1 aa99–163 Interaction Site Suppresses polyQ-Expanded Protein Dimerization
Spinocerebellar ataxia type 1 (SCA1) is a neurodegenerative disease caused by the expansion of a polyglutamine (polyQ) tract in the ATXN1 protein. This expansion is thought to be responsible for the gradual aggregation of the mutant protein, which is associated with increased cytotoxicity and neuronal cell death. Apart from the polyQ tract, other domains in ATXN1 are also involved in the initial events of protein aggregation, such as a dimerization domain that promotes protein oligomerization. ATXN1 interacts with various proteins; among them, MED15 significantly enhances the aggregation of the polyQ-expanded protein. Therefore, we set to identify the interaction site between ATXN1 and MED15 and assess whether its chemical targeting would affect polyQ protein aggregation. First, we predicted the structures of ATXN1 and MED15 and simulated their interaction. We experimentally validated that amino acids (aa) 99–163 of ATXN1 and aa548–665 of MED15 are critical for this protein–protein interaction (PPI). We also showed that the aa99–163 domain in ATXN1 is involved in the dimerization of the mutant isoform. Targeting this domain with a chemical compound identified through virtual screening (Chembridge ID: 5755483) inhibited both the interaction of ATXN1 with MED15 and the dimerization of polyQ-expanded ATXN1. These results strengthen our assumption that the aa99–163 domain of ATXN1 may be involved in polyQ protein aggregation and highlight compound 5755483 as a potent first-in-class therapeutic agent for SCA1.
- 17 June 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (25) , 27194-27205
Open AccessChemical Targeting of the ATXN1 aa99–163 Interaction Site Suppresses polyQ-Expanded Protein Dimerization
Spinocerebellar ataxia type 1 (SCA1) is a neurodegenerative disease caused by the expansion of a polyglutamine (polyQ) tract in the ATXN1 protein. This expansion is thought to be responsible for the gradual aggregation of the mutant protein, which is associated with increased cytotoxicity and neuronal cell death. Apart from the polyQ tract, other domains in ATXN1 are also involved in the initial events of protein aggregation, such as a dimerization domain that promotes protein oligomerization. ATXN1 interacts with various proteins; among them, MED15 significantly enhances the aggregation of the polyQ-expanded protein. Therefore, we set to identify the interaction site between ATXN1 and MED15 and assess whether its chemical targeting would affect polyQ protein aggregation. First, we predicted the structures of ATXN1 and MED15 and simulated their interaction. We experimentally validated that amino acids (aa) 99–163 of ATXN1 and aa548–665 of MED15 are critical for this protein–protein interaction (PPI). We also showed that the aa99–163 domain in ATXN1 is involved in the dimerization of the mutant isoform. Targeting this domain with a chemical compound identified through virtual screening (Chembridge ID: 5755483) inhibited both the interaction of ATXN1 with MED15 and the dimerization of polyQ-expanded ATXN1. These results strengthen our assumption that the aa99–163 domain of ATXN1 may be involved in polyQ protein aggregation and highlight compound 5755483 as a potent first-in-class therapeutic agent for SCA1.